Aaron Mendelsohn

Mr. Mendelsohn has been involved in financing in the medical field, including several Al Mann companies such as MiniMed, MRG, and Advanced Bionics. He is a founder and, since its inception, has been a director for Second Sight Medical Products, a publicly-traded company that developed and commercialized the world's first prosthetic retinal stimulator that restores some useful vision to the profoundly blind. He served as a director of MRG from its formation in 1998 until it was sold in 2001 to Medtronic, Inc. He served on the board of Advanced Bionics for many years until it was sold to Boston Scientific in 2004. He served as a director of the Alfred Mann Institute for Biomedical Engineering at USC from its inception in 1998 until after Al’s death in 2016. During that time, he was a member of the 3-man committee that served as the CEO. He is a founder of Mastacopia, S.A., a start-up company that has developed a new and better method of breast cancer screening currently in testing at a Harvard University hospital.

Mr. Mendelsohn also is a founder and has served as Chairman of the Maestro Foundation since it was organized in 1983. The Maestro foundation is a leading non-profit musical philanthropic organization that hosts what is considered to be the nation’s premier chamber music series and has an active instrument lending program that lends approximately 100 professional-level string instruments and bows to young, career-bound classical musicians. Mr. Mendelsohn holds a Bachelor’s Degree with honors from UCLA and holds a JD from Loyola University School of Law.